全文获取类型
收费全文 | 61093篇 |
免费 | 6958篇 |
国内免费 | 4661篇 |
学科分类
医药卫生 | 72712篇 |
出版年
2024年 | 90篇 |
2023年 | 1060篇 |
2022年 | 1472篇 |
2021年 | 2978篇 |
2020年 | 2582篇 |
2019年 | 2238篇 |
2018年 | 2250篇 |
2017年 | 2090篇 |
2016年 | 1976篇 |
2015年 | 2972篇 |
2014年 | 3695篇 |
2013年 | 3158篇 |
2012年 | 4891篇 |
2011年 | 5276篇 |
2010年 | 3133篇 |
2009年 | 2413篇 |
2008年 | 3341篇 |
2007年 | 3249篇 |
2006年 | 3170篇 |
2005年 | 3123篇 |
2004年 | 2030篇 |
2003年 | 1972篇 |
2002年 | 1622篇 |
2001年 | 1389篇 |
2000年 | 1430篇 |
1999年 | 1634篇 |
1998年 | 986篇 |
1997年 | 956篇 |
1996年 | 694篇 |
1995年 | 651篇 |
1994年 | 648篇 |
1993年 | 401篇 |
1992年 | 567篇 |
1991年 | 431篇 |
1990年 | 394篇 |
1989年 | 330篇 |
1988年 | 322篇 |
1987年 | 249篇 |
1986年 | 214篇 |
1985年 | 182篇 |
1984年 | 98篇 |
1983年 | 60篇 |
1982年 | 45篇 |
1981年 | 41篇 |
1980年 | 20篇 |
1979年 | 42篇 |
1978年 | 16篇 |
1977年 | 14篇 |
1964年 | 7篇 |
1936年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Evolutionary Action Score of TP53 Enhances the Prognostic Prediction for Stage I Lung Adenocarcinoma
Yue Zhao Han Han Zhendong Gao Hong Hu Jiaqing Xiang Yihua Sun Haiquan Chen 《Seminars in thoracic and cardiovascular surgery》2021,33(1):221-229
Study overview. 83 patients with stage I lung adenocarcinoma were included in this study. Whole-exome sequencing was performed on surgical samples of these patients. Patients were further divided into 4 groups according to their TP53 mutational status. Tumor mutational burden, recurrence-free survival and overall survival were compared among different groups. 相似文献
102.
103.
104.
Kishor Devalaraja-Narashimha Karoline Meagher Yifan Luo Cong Huang Theodore Kaplan Anantharaman Muthuswamy Gabor Halasz Sarah Casanova John OBrien Rebecca Peyser Boiarsky John McWhirter Hans Gartner Yu Bai Scott MacDonnell Chien Liu Ying Hu Adrianna Latuszek Yi Wei Srinivasa Prasad Tammy Huang George Yancopoulos Andrew Murphy William Olson Brian Zambrowicz Lynn Macdonald Lori G. Morton 《Journal of the American Society of Nephrology : JASN》2021,32(1):99
105.
106.
107.
Zhi-Chen Guo Sakendeke Jumatai Si-Li Jing Lu-Lu Hu Xin-Yu Jia Zhong-Cheng Gong 《Oncology Letters》2021,21(3)
The present study aimed to detect the immunoexpression and clinical significance of Porphyromonas gingivalis (P. gingivalis) in the tumor microenvironment (TME) of oral squamous cell carcinoma (OSCC). The immunoexpression of P. gingivalis in OSCC tissues was detected via immunohistochemistry (IHC) after P. gingivalis was infected into the TME of OSCC. To identify the differentially expressed genes in the carcinogenesis and progression of OSCC with P. gingivalis infection, microarray datasets ( and GSE87539) were downloaded from the Gene Expression Omnibus database. The immunoexpression levels of C-X-C motif chemokine ligand 2 (CXCL2) and tumor-associated neutrophils (TANs) were also evaluated via IHC, and the immunoexpression levels of all three clinical variables were analyzed using χ2 or Fisher''s exact tests. The survival rates were calculated using the Kaplan-Meier method and the survival curves were compared using log-rank tests. Predominantly strong immunoexpression of P. gingivalis was identified in OSCC samples. CXCL2 was considered to be a differential gene in the two datasets. Immunoexpression of P. gingivalis was positively associated with CXCL2 and TANs expression. Furthermore, P. gingivalis was associated with survival status (P<0.001) and differentiation (P<0.001). CXCL2 was associated with age (P=0.038) and survival status (P=0.003), while TANs were associated with T stage (P=0.015) and clinical stage (P=0.002). These clinical variables were considered to be independent risk factors for the poor prognosis of patients with OSCC. Collectively, the results suggested that the immunoexpression of P. gingivalis may be positively associated with CXCL2 and TANs. In addition, the strong immunoexpression levels of P. gingivalis, CXCL2 and TANs may be associated with a poor prognosis in patients with OSCC. GSE138206相似文献
108.
Xiaofei Ye Fangyuan Hu Yinghong Zhai Yingyi Qin Jinfang Xu Xiaojing Guo Yonglong Zhuang Jia He 《Hematological oncology》2020,38(4):565-575
Immune checkpoint inhibitors (ICIs) have shown remarkable clinical effects in many cancer types. However, ICIs could also induce severe organ system toxicities, including those of the hematological system. The present study aimed to extensively characterize the hematological toxicities of ICIs immunotherapy. Data were extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database from January 1, 2014, to March 31, 2019. Disproportionality analysis, including information component (IC) and reporting odds ratio (ROR), was used to detect potential disproportionality signal. The lower boundary of the 95% confidence interval of IC (IC025) exceeding zero or that of ROR (ROR025) exceeding one was considered statistically significant for detecting disproportionality signal. A total of 29 294 335 records were extracted from the database, with 132 573 related to ICIs. Overall, hematological adverse events (AEs) were more frequently reported in ICIs (IC025: 0.81; ROR025: 1.80). On further analysis, hematological AEs were overreported in female patients (female vs male, ROR025: 1.04) and anti-CTLA-4 monotherapy groups (anti-CTLA-4 vs anti-PD-1, ROR025: 1.33) and polytherapy groups (polytherapy vs monotherapy, ROR: 1.20, ROR025: 1.11). Moreover, class-specific hematological AEs were also detected and differed in unique ICI regimens. Notably, disseminated intravascular coagulation had the highest proportion of death outcomes among the top 10 most frequently reported ICI-associated hematological AEs. Our study shows a high reporting frequency of hematological AEs induced by ICI monotherapy (especially by anti-CTLA-4 therapy) and reinforced by polytherapy. A spectrum of class-specific disproportionality signal was also detected; some were fatal and reported for the first time. The heterogeneous clinical spectrum of hematological toxicities, including the non-negligible proportion of death as reported outcome, are warranted to be reminded by clinicians. Early recognition and management of ICI-related hematological AEs are highly important and further studies are needed to confirm the results of our study. 相似文献
109.
目的 本研究旨在探讨气不摄血证免疫性血小板减少症(ITP)患者血管活性物质及相关炎症因子在ITP发病中的作用及其临床意义。方法 气不摄血证ITP患者30例(ITP组),根据2016版ITP出血评分量表,分为未出血组、低危组(≤2分)及高危组(>2分),健康正常人20例(对照组)。酶联免疫吸附(ELISA)法检测外周血血管活性物质一氧化氮(NO)、一氧化氮合成酶(NOS)及内皮素-1(ET-1)含量,AimPlex流式高通量技术检测外周血血管活性物质VEGF-A,VEGF-D及相关炎症因子IL-8,IL-10,IL-17A以及TNF-α含量。结果 与对照组相比较,气不摄血证ITP患者NOS、VEGF-A及IL-10含量显著降低(P<0.05),ET-1、IL-8、IL-17A以及TNF-α含量显著升高(P<0.05)。同时,气不摄血证ITP患者中,高危组ET-1含量显著高于未出血组(P<0.05),ET-1、VEGF-A含量与气不摄血证ITP患者出血显著相关(OR=1.012,95%CI:0.92-1.31;OR=1.065, CI:0.98-1.22,P<0.05)。结论 血管活性物质及相关炎症因子在气不摄血证ITP患者的发病过程中具有重要作用,ET-1、VEGF-A可能是反应气不摄血证ITP患者出血风险的重要客观指标。 相似文献
110.
目的 初步探讨HPV检测在诊断原发灶不明的颈淋巴结转移性鳞癌中的价值。方法 收集复旦大学附属肿瘤医院6例首诊为原发灶不明的颈淋巴结转移性鳞癌,最终确诊为HPV相关口咽鳞癌,分析确诊过程。结果 首诊时6例患者均被确诊为颈淋巴结转移性鳞癌,且p16表达阳性和HPV-16亚型阳性,而EBER表达阴性。经全面检查均未发现明显的原发病灶。随后对其中4例予同侧扁桃体盲检(2例)和切除(2例),病理均证实为扁桃体鳞癌。另2例分别在随访第149天、545天MRI检查发现同侧口咽侧壁和舌根增厚伴强化,经活检分别证实为扁桃体鳞癌、舌根鳞癌。结论 对于原发灶不明的HPV阳性颈淋巴结转移性鳞癌,应高度怀疑原发病灶来源于口咽部位的可能性,特别是扁桃体和舌根部位。 相似文献